Professional Media briefs: May 2013

Share this article:
The American Diabetes Association is launching its official open-access publication this spring, reported Gorkana. The peer-reviewed title BMJ Open Access Diabetes Research and Care will cover type 1 and 2 diabetes and their complications. The publication, which is in the process of finding an editor-in-chief, put out an all-points call for applications; the deadline was April 1.

MedCityNews and UBM Medica are partnering up to put MedCity's Health IT content in the hands of UBM's Partner Network, which spans 30 specialties and therapeutic areas. UBM spokesperson Amy Erdman told MM&M via email that the partnership “is a great fit for our relevant readers as well as our advertisers” and aligns with a push to increase advertising reach to authenticated HCPs.

American College of Physicians advertising director Kevin ­Bolum and JAMA's derma­tology and internal medicine account manager, Patricia Quilty, respectively snagged the Multi-Specialty and Specialty Nexus Awards in March. The awards are for excellence and for promoting the effectiveness of journal advertising. The Association of Medical Media started the award in 1993.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?